Deltec Asset Management LLC Purchases 100,000 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Deltec Asset Management LLC boosted its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 3.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,716,373 shares of the biopharmaceutical company's stock after acquiring an additional 100,000 shares during the period. Ocular Therapeutix accounts for 4.2% of Deltec Asset Management LLC's portfolio, making the stock its 4th largest position. Deltec Asset Management LLC owned approximately 1.71% of Ocular Therapeutix worth $19,911,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the stock. Assenagon Asset Management S.A. bought a new stake in Ocular Therapeutix during the 1st quarter valued at $2,505,000. Courier Capital LLC raised its position in shares of Ocular Therapeutix by 173.3% during the first quarter. Courier Capital LLC now owns 154,266 shares of the biopharmaceutical company's stock worth $1,131,000 after purchasing an additional 97,828 shares during the period. Rhumbline Advisers increased its position in shares of Ocular Therapeutix by 4.5% in the first quarter. Rhumbline Advisers now owns 223,115 shares of the biopharmaceutical company's stock worth $1,635,000 after acquiring an additional 9,514 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Ocular Therapeutix by 6,760.0% in the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 8,112 shares during the period. Finally, Wellington Management Group LLP increased its stake in Ocular Therapeutix by 1.0% in the 4th quarter. Wellington Management Group LLP now owns 467,352 shares of the biopharmaceutical company's stock valued at $3,991,000 after buying an additional 4,488 shares during the period. Institutional investors own 59.21% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on OCUL. William Blair began coverage on shares of Ocular Therapeutix in a report on Tuesday, April 8th. They issued an "outperform" rating for the company. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Ocular Therapeutix in a report on Thursday, May 29th. Needham & Company LLC decreased their target price on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Finally, Royal Bank Of Canada began coverage on shares of Ocular Therapeutix in a report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price target for the company. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Ocular Therapeutix presently has a consensus rating of "Buy" and an average price target of $17.33.

Ocular Therapeutix Stock Up 8.6%

Shares of NASDAQ:OCUL traded up $0.72 during midday trading on Tuesday, hitting $9.09. The stock had a trading volume of 4,771,509 shares, compared to its average volume of 1,419,362. The company has a market cap of $1.45 billion, a P/E ratio of -7.90 and a beta of 1.42. The company has a quick ratio of 10.14, a current ratio of 10.22 and a debt-to-equity ratio of 0.26. The business's 50-day simple moving average is $7.89 and its 200-day simple moving average is $7.81. Ocular Therapeutix, Inc. has a 12 month low of $5.79 and a 12 month high of $11.78.

Insider Activity

In related news, insider Pravin Dugel sold 21,219 shares of the company's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $7.18, for a total transaction of $152,352.42. Following the completion of the sale, the insider now directly owns 3,499,099 shares in the company, valued at $25,123,530.82. This represents a 0.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Richard L. Md Lindstrom bought 10,000 shares of the firm's stock in a transaction on Thursday, May 8th. The stock was acquired at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the transaction, the director now owns 172,704 shares of the company's stock, valued at approximately $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 29,079 shares of company stock valued at $208,739 over the last ninety days. 2.30% of the stock is currently owned by company insiders.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.